Hepatitis C virus and hepatocarcinogenesis

Intervirology

Volumn 42, Issue 2-3, 1999, Pages 205-210

  Hayashi, Junpei ^a,b   Aoki, Hiroshi ^a,b   Arakawa, Yasuyuki ^b   Hino, Okio ^a  

^a CANCER INSTITUTE   (Japan)

^b NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Hepatitis; Hepatitis C virus; Hepatocarcinogenesis; Hepatocellular carcinoma; Signal transduction

Indexed keywords

CYTOKINE; PROTEIN P53; SOMATOMEDIN B;

APOPTOSIS; CANCER CELL; CELL PROLIFERATION; CHRONIC INFLAMMATION; CYTOLOGY; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOLOGY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MOLECULAR BIOLOGY; ONCOGENE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

CHROMOSOME ABERRATIONS; HEPATITIS C; HUMANS; LIVER NEOPLASMS; LOSS OF HETEROZYGOSITY; SIGNAL TRANSDUCTION;

EID: 0032826830     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000024962     Document Type: Review

References (43)

1. Saito I, Miyamura T, Ohbayashi A, Harada H, Katayama T, Kikuchi S, Watanabe Y, Koi S, Onji M, Ohta Y, Choo Q-L, Houghton M, Kuo G: Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci USA 1990;87:6547-6549.
2. Tsukuma H, Hiyama T, Tanaka S, Naoko M, Yahuuchi T, Kitamura T, Nakanishi K, Fujimoto I, Inoue A, Yamazaki H, Kawashima T: Risk factor for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993;328:1791-1801.
3. Manjia A, Vallari DS, Di Bisceglie AM: Use of confirmatory assays for diagnosis of hepatitis C viral infection in patients with hepatocellular carcinoma. J Med Virol 1994; 43:125-128.
4. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M: Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244:359-362.
5. Kajino K, Aoki H, Hino O: Genomic instability involved in virus-related hepatocarcinogenesis. Intervirology 1995;38:170-172.
6. Ruggieri A, Harada T, Matsuura Y, Miyamura T: Sensitization to Fas-mediated apoptosis by hepatitis C virus core protein. Virology 1997; 229:68-76.
7. Hino O, Yamamoto T, Kajino K: Inflammation: Mediated hepatocarcinogenesis-hypercarcinogenic state of chronic liver disease. Prog Hepatol 1998;4:35-39.
8. Hiroishi K, Kita H, Kojima M: Cytotoxic T lymphocyte response and viral load in hepatitis C virus interferon. Hepatology 1997;25:705-712.
9. Ogata N, Alter HJ, Miller RH, Purcell RH: Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc Natl Acad Sci USA 1994;88:3392-3396.
10. Kato N, Ootsuyama Y, Sekiya H, Ohkoshi S, Nakazawa T, Hijikata M, Shimotohono K: Genetic drift in hypervariable region 1 of the viral genome in persistent hepatitis C virus infection. J Virol 1994;68:4776-4784.
11. Kuzushita N, Hayashi N, Moribe T, Katayama K, Kanto T, Nakatani S, Kaneshige T, Tatumi T, Ho A, Mochizuki K, Sasaki Y, Kasahara A, Hori M: Influence of HLA haplotypes on the clinical course of individuals infected with hepatitis C virus. Hepatology 1998;27:240-244.
12. Zhu N, Khoshnan A, Schneider R, Matsumoto M, Dennert G, Ware C, Lai MM: Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis. J Virol 1998;72:3691-3697.
13. Ray RB, Meyer K, Steele R, Shrivastava A, Aggarwal BB, Ray R: Inhibition of tumor necrosis factor (TNF-α)-mediated apoptosis by hepatitis C virus core protein. J Biol Chem 1998;273:2256-2259.
14. Matsumoto M, Hsieh TY, Zhu N, Van Arsdale T, Hwang SB, Jeng KS, Gorbalenya AE, Lo SY, Ou JH, Ware CF, Lai MM: Hepatitis C virus core protein interacts with the cytoplasmic tail of lymphotoxin-β receptor. J Virol 1997;71: 1301-1309.
15. Wakita T, Taya C, Katsume A, Kato J, Yonekawa H, Kanegane Y, Saito I, Hayashi Y, Koike M, Kohara M: Efficient conditional transgene expression in hepatitis C virus cDNA transgenic mice mediated by the Cre/loxP system. J Biol Chem 1998;273:9001-9006.
16. Kyoji M, Fujie H, Shintani Y, Yotuyanagi H, Tutumi T, Ishibashi K, Matuura Y, Kimura S, Miyamura T, Koike K: The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998;4: 1065-1067.
17. Kuroki T, Fujiwara Y, Tsuchiya E, Imaoka S, Kaneniatsu T, Nakamura Y: Accumulation of genetic changes during development and progression of hepatocellular carcinoma: Loss of heterozygosity on chromosome arm 1p occurs at an early stage of hepatocarcinogenesis. Genes Chromosomes Cancer 1995;13:163-167.
18. Nishida N, Fukuda Y, Ishizaki K, Nakao K: Alteration of cell cycle-related genes in hepatocarcinogenesis. Histol Histopathol 1997;12: 1019-1025.
19. Piao Z, Kim H, Jeon BK, Lee WJ, Park C: Relationship between loss of heterozygosity of tumor suppressor genes and histologic differentiation in hepatocelluar carcinoma. Cancer 1997;80:865-872.
20. Kishimoto Y, Shiota G, Kamisaki Y, Wada K, Nakamoto K, Yamawaki M, Kotani M, Itoh T, Kawasaki H: Loss of tumor suppressor p53 gene at the liver cirrhosis stage in Japanese patients with hepatocellular carcinoma. Oncology 1997;54:304-310.
21. Zhang X, Xu HJ, Murakami Y, Sachse R, Yashima K, Hirohashi S, Hu SX, Benedict WF, Sekiya T: Deletions of chromosome 13q, mutations in retinoblastoma 1, and retinoblastoma protein state in human hepatocellular carcinoma. Cancer Res 1994;54:4177-4182.
22. Nishida N, Fukuoka Y, Kokuryu H, Sadamoto T, Isowa G. Honda K, Yamaoka T, Ikenaga M, Imura H, Ishizaki K: Accumulation of allelic loss arms of arm of chromosomes 13q, 16q and 17q in the advanced stage of human hepatocellular carcinoma. Int J Cancer 1997;51:862-868.
23. De Souza AT, Hankins GR, Washington MK, Fine RL, Orton TC, Jirtle RL: Frequent loss of heterozygosity on 6q at the mannose 6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors. Oncogene 1995;10:1725-1729.
24. De Souza AT, Hankins GR, Washington MK, Orton TC, Jirtle RL: M6P/1GF2R gene is mutated in human hepatocelluar carcinomas with loss of heterozygosity. Nat Genet 1995;11:447-449.
25. Yamada T, De Souza AT, Finkelstein S, Jirtle RL: Loss of the gene encoding mannose 6-phoshate/insulin-like growth factor II receptor is an early event in liver carcinogenesis. Proc Natl Acad Sci USA 1997;94:10351-10355.
26. Li X, Nong Z, Ekstrom C, Larsson E, Nordlinder H, Hofmann WJ, Trautwein C, Odenthal M, Dienes HP, Ekstrom TJ, Schirmacher P: Disrupted IGF2 promoter control by silencing of promoter P1 in human hepatocellular carcinoma. Cancer Res 1997;57:2048-2054.
27. Uchida K, Kondo M, Takeda S, Osada H, Takahashi T, Nakao A, Takahashi T: Altered transcriptional regulation of the insulin-like growth factor-2 gene in human hepatocellular carcinoma. Mol Carcinog 1997;18:193-198.
28. Schlott T, Reimer S, Jahns A, Ohlenbusch A, Ruschenburg I, Nagel H, Droese M: Point mutations and nucleotide insertions in the MDM2 zinc finger structure of human tumors. J Pathol 1997;182:54-61.
29. Yamashita N, Ishibashi H, Hayashida K, Kudo J, Takenaka K, Itoh K, Niho Y: High frequency of the MAGE-1 gene expression in hepatocellular carcinoma. Hepatology 1996;24:1437-1440.
30. Hsu HC, Cheng W, Lai PL: Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: Biological significance and temporospatial distribution. Cancer Res 1997;57:5179-5184.
31. Ueki T, Fujimoto J, Suzyki T: Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma. Hepatology 1997;25:862-866.
32. Chuang LY, Hung WC, Yang ML, Chang CC, Tsai JF: Urinary EGF-receptor-binding growth factors in patients with cancers of the digestive tract. Clin Biochem 1994;27:485-489.
33. Miller RT, Cattley RC, Marsman DS, Lyght O, Popp JA: TGF-alpha differentially expressed in the liver foci induced by diethylnitrosamine initiation and peroxisome proliferation promotor. Carcinogenesis 1995;16:77-82.
34. El-Shemerly MYM, Besser D, Nagasawa M, Nagamine Y: 12-O-tetradecanoylphorbol-13-acetate activates the Ras/extracellular signal-regulated kinase (ERK) signaling pathway upstream of SOS involving serine phosphorylation of She in NIH3T3 cells. J Biol Chem 1997; 272:30599-30602.
35. Ito Y, Sasaki Y, Horimoto M, Wada S, Tanaka Y, Kasahara A, Ueji T, Hirano T, Yamamoto H, Fujimoto J, Okamoto E, Hayashi N, Hori M: Activation of mitogen-activated protein kinase/extracellular signal-regulated kinase in human hepatocellular carcinoma. Hepatology 1998;27:951-958.
36. Karin M: The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem 1995;270:16483-16486.
37. de la Coste A, Romagnolo B, Billuart P, Renard CA, Buendia MA, Soubrane O, Fabre M, Chelly J, Beldjord C, Kahn A, Perret C: Somatic mutations of the β-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 1998;95:8847-8851.
38. Doria M, Klein N, Lucito R, Schnider RJ: The hepatitis B HBx protein is a dual specificity cytoplasmic activator of Ras and nuclear activator of transcription factor. EMBO J 1995;14: 4747-4757.
39. Ueda H, Ullrich SJ, Gangemi JD, Kappel CA, Ngo L, Feitelson MA, Jay G: Functional inactivation but not structural mutation of p53 causes liver cancer. Nat Genet 1995;9:41-47.
40. Ray RB, Lagging LM, Meyer K, Ray R: Hepatitis C virus core protein cooperates with ras and transforms primary rat embryo fibroblasts to tumorigenic phenotype. J Virol 1996;265: 4438-4443.
41. Kato N, Lan KH, Ono-Nita SK, Shiratori Y, Omata M: Hepatitis C virus nonstructural region 5A protein is a potent transcriptional activator. J Virol 1997;71:8856-8859.
42. Sakamuro D, Furukawa T, Takegami T: Hepatitis C virus nonstructural protein NS3 transforms NIH3T3 cells. J Virol 1995;69:3893-3896.
43. Gale MJ, Korth MJ, Tang NM, Tan SL, Hopkins DA, Dever TE, Polyak SJ, Gretch DR, Katze MG: Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 1998;230: 217-227.